Shares of the company are trading at $1.35 which is just over $1.29, the stock’s 50 day moving average and which is well below the 200 day moving average of $1.95. The 50 day moving average was up by +4.77% and the 200 day average went down by -30.73%. 365 shares changed hands on Tuesday. Trading volume was down 92.64% under the stocks average daily volume.
Investors are a little more bullish on shares of ARCA biopharma, Inc. recently as evidenced by the fall in short interest. The company had a fall in short interest of -2.66% between September 15, 2017 and September 29, 2017. Short shares decreased 3,724 over that timeframe. The short-interest ratio decreased to 3.0 and the percentage of shorted shares was 0.01% on September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (ABIO). As of quarter end Goldman Sachs Group Inc had disposed of 558 shares trimming its holdings by 3.3%. The value in dollars decreased from $43,000 to $39,000 a change of 9.3% quarter over quarter. As of the end of the quarter Royce & Associates Lp had bought a total of 148,647 shares growing its position 476.4%. The value of the investment in ARCA biopharma, Inc. went from $78,000 to $441,000 a change of $363,000 since the last quarter.
Renaissance Technologies LLC grew its investment by buying 23,700 shares an increase of 77.4% from 03/31/2017 to 06/30/2017. Renaissance Technologies LLC owns 54,326 shares with a value of $130,000. The total value of its holdings increased 66.7%. As of the end of the quarter Blackrock Inc. had sold 14,133 shares trimming its stake by 94.2%. The value of the company’s investment in ARCA biopharma, Inc. decreased from $38,000 to $2,000 decreasing 94.7% for the reporting period.
ARCA biopharma, Inc. (ARCA), launched on March 16, 2004, is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Business’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors..